313 related articles for article (PubMed ID: 29992570)
1. A novel tumor-based epithelial-to-mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer.
Roseweir AK; Kong CY; Park JH; Bennett L; Powell AGMT; Quinn J; van Wyk HC; Horgan PG; McMillan DC; Edwards J; Roxburgh CS
Int J Cancer; 2019 Jan; 144(1):150-159. PubMed ID: 29992570
[TBL] [Abstract][Full Text] [Related]
2. The relationship between the Glasgow Microenvironment Score and markers of epithelial-mesenchymal transition in TNM II-III colorectal cancer.
Alexander PG; Matly AAM; Jirapongwattana N; Pennel KAF; van Wyk HC; McMillan DC; Horgan PG; Roxburgh CSD; Thuwajit C; Roseweir AK; Quinn J; Park JH; Edwards J
Hum Pathol; 2022 Sep; 127():1-11. PubMed ID: 35623467
[TBL] [Abstract][Full Text] [Related]
3. Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition.
Yamada N; Sugai T; Eizuka M; Tsuchida K; Sugimoto R; Mue Y; Suzuki M; Osakabe M; Uesugi N; Ishida K; Otsuka K; Matsumoto T
Hum Pathol; 2017 Feb; 60():151-159. PubMed ID: 27836787
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
[TBL] [Abstract][Full Text] [Related]
5. Microenvironmental interactions and expression of molecular markers associated with epithelial-to-mesenchymal transition in colorectal carcinoma.
Lee SJ; Yang CS; Kim DD; Kang YN; Kwak SG; Park JB; Cho CH; Park KK
Int J Clin Exp Pathol; 2015; 8(11):14270-82. PubMed ID: 26823743
[TBL] [Abstract][Full Text] [Related]
6. Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: Clinicopathological significance.
Choi JE; Bae JS; Kang MJ; Chung MJ; Jang KY; Park HS; Moon WS
Oncol Rep; 2017 Sep; 38(3):1695-1705. PubMed ID: 28677737
[TBL] [Abstract][Full Text] [Related]
7. TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-β1.
Kim YH; Kim G; Kwon CI; Kim JW; Park PW; Hahm KB
Oncol Rep; 2014 Mar; 31(3):1380-8. PubMed ID: 24402192
[TBL] [Abstract][Full Text] [Related]
8. Tenascin-C as a prognostic determinant of colorectal cancer through induction of epithelial-to-mesenchymal transition and proliferation.
Yang Z; Zhang C; Qi W; Cui C; Cui Y; Xuan Y
Exp Mol Pathol; 2018 Oct; 105(2):216-222. PubMed ID: 30170017
[TBL] [Abstract][Full Text] [Related]
9. Cancer Stemness, Immune Cells, and Epithelial-Mesenchymal Transition Cooperatively Predict Prognosis in Colorectal Carcinoma.
Xu F; Li S; Zhang J; Wang L; Wu X; Wang J; Huang Q; Lai M
Clin Colorectal Cancer; 2018 Sep; 17(3):e579-e592. PubMed ID: 29921496
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of SIX1 is an independent prognostic marker in stage I-III colorectal cancer.
Kahlert C; Lerbs T; Pecqueux M; Herpel E; Hoffmeister M; Jansen L; Brenner H; Chang-Claude J; Bläker H; Kloor M; Roth W; Pilarsky C; Rahbari NN; Schölch S; Bork U; Reissfelder C; Weitz J; Aust D; Koch M
Int J Cancer; 2015 Nov; 137(9):2104-13. PubMed ID: 25951369
[TBL] [Abstract][Full Text] [Related]
11. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis.
Yokobori T; Iinuma H; Shimamura T; Imoto S; Sugimachi K; Ishii H; Iwatsuki M; Ota D; Ohkuma M; Iwaya T; Nishida N; Kogo R; Sudo T; Tanaka F; Shibata K; Toh H; Sato T; Barnard GF; Fukagawa T; Yamamoto S; Nakanishi H; Sasaki S; Miyano S; Watanabe T; Kuwano H; Mimori K; Pantel K; Mori M
Cancer Res; 2013 Apr; 73(7):2059-69. PubMed ID: 23378342
[TBL] [Abstract][Full Text] [Related]
12. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer.
Galván JA; Helbling M; Koelzer VH; Tschan MP; Berger MD; Hädrich M; Schnüriger B; Karamitopoulou E; Dawson H; Inderbitzin D; Lugli A; Zlobec I
Oncotarget; 2015 Jan; 6(2):874-85. PubMed ID: 25528769
[TBL] [Abstract][Full Text] [Related]
13. MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.
Su L; Luo Y; Yang Z; Yang J; Yao C; Cheng F; Shan J; Chen J; Li F; Liu L; Liu C; Xu Y; Jiang L; Guo D; Prieto J; Ávila MA; Shen J; Qian C
Cancer Res; 2016 Sep; 76(17):5054-67. PubMed ID: 27364559
[TBL] [Abstract][Full Text] [Related]
14. Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Yang J; Zhang K; Song H; Wu M; Li J; Yong Z; Jiang S; Kuang X; Zhang T
Oncotarget; 2016 May; 7(22):32306-17. PubMed ID: 27058759
[TBL] [Abstract][Full Text] [Related]
15. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
16. The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC).
Wang Y; Wu Z; Hu L
Eur J Pharmacol; 2018 Sep; 834():45-53. PubMed ID: 30017802
[TBL] [Abstract][Full Text] [Related]
17. ΔNp63α attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma.
Zhao W; Wang H; Han X; Ma J; Zhou Y; Chen Z; Zhou H; Xu H; Sun Z; Kong B; Fang H
Tumour Biol; 2016 Aug; 37(8):10621-32. PubMed ID: 26864590
[TBL] [Abstract][Full Text] [Related]
18. Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transition.
Feng M; Feng J; Chen W; Wang W; Wu X; Zhang J; Xu F; Lai M
Mol Cancer; 2016 Dec; 15(1):77. PubMed ID: 27912767
[TBL] [Abstract][Full Text] [Related]
19. HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.
Desai K; Aiyappa R; Prabhu JS; Nair MG; Lawrence PV; Korlimarla A; Ce A; Alexander A; Kaluve RS; Manjunath S; Correa M; Srinath BS; Patil S; Kalamdani A; Prasad M; Sridhar TS
Tumour Biol; 2017 Mar; 39(3):1010428317695028. PubMed ID: 28349782
[TBL] [Abstract][Full Text] [Related]
20. ILEI: a novel marker for epithelial-mesenchymal transition and poor prognosis in colorectal cancer.
Gao ZH; Lu C; Wang ZN; Song YX; Zhu JL; Gao P; Sun JX; Chen XW; Wang MX; Dong YL; Xu HM
Histopathology; 2014 Oct; 65(4):527-38. PubMed ID: 24738665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
